Eastman Chemical Company

CEO Mark Costa and team navigated a weak cycle while preserving cash generation, defending price in specialties, and accelerating structural cost reductions. Execution on Kingsport methanolysis improved through 2025 with on‑spec output and operational scaling; management is re‑sequencing growth to fit returns and policy clarity.

Room to improve remains in reducing CI volatility and translating circular wins to steadier earnings growth.